Free Biopharma Daily Stock Updates - 07/21/21

$XBI $130.25 +1.0%

---

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

---

Covid Updates

$PFE +-0.0%Pfizer and BioNTech Announce Collaboration with Biovac to Manufacture and Distribute COVID-19 Vaccine Doses within Africa source

$SRNE +8.40% Sorrento Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS, a Highly Potent Neutralizing Antibody Against SARS-CoV-2 Including Delta and Alpha Variants of Concern, in an At-Home Outpatient Setting in United Kingdom source

$ORMP +9.7% Oramed Provides Update on Oravax: Oral Vaccine Maker Gets IRB Approval for Clinical Trial source

Pipeline Updates

$BLUE +0.60% bluebird bio Receives EC Approval for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age With Early Cerebral Adrenoleukodystrophy (CALD) Without Matched Sibling Donor source

$INZY +5.2% Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the European Medicines Agency for the Treatment of ABCC6 Deficiency source

$ARQT -1.1% Arcutis Advances Science of Psoriasis Drug Development with New Precision Method for Measuring Mild-to-Moderate Psoriasis source

$VIRX +1.6% Viracta Therapeutics Announces FDA Clearance of IND Application for Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors source

$MRUS +5.4% Merus Announces Publication in Nature Communications on MCLA-145’s Novel Mechanism of Action Promoting Tumor Immunity and Context Dependent T-Cell Costimulation source

$CRTX +6.0% Cortexyme Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021 source

$MGTA -9.3% Magenta Therapeutics Announces Update On U.s. Fda Investigational New Drug Application For Mgta-117 In Patients With Acute Myeloid Leukemia And Myelodysplastic Syndrome source

$DRNA -3.7% Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease source

$APRE -5.5% Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML source

$KMPH +2.2% KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc source

$SAVA +29.5% Cassava Sciences to Present New Clinical Dataset at 2021 Alzheimer’s Association International Conference source

$SRNE +8.40% Sorrento Announces That Its Subsidiary Levena and Its Partner Escugen Have Received Clearance to Begin Clinical Trials With Anti-TROP-2 Antibody Drug Conjugate For Multiple Solid Tumors source

$ERYP +0.2% Erytech Confirms Plans To Submit Bla For Eryaspase In Hypersensitive All Patients source

$HRTX +3.6% Heron Therapeutics Announces Publication Showing Reduction of Pain and Opioid Use Compared to Bupivacaine in Patients 65 and Older with ZYNRELEF™ source

$ALEC -7.0% Alector to Present New Data from Frontotemporal Dementia and Alzheimer’s Disease Programs at the 2021 Alzheimer’s Association International Conference source

$ACAD -2.2% The New England Journal of Medicine Publishes Results from the Phase 3 HARMONY Study Evaluating Pimavanserin in Patients with Dementia-Related Psychosis source

Financial Updates

$AZNF -.60% Acquisition of Alexion completed source

---

Posted by JM